Moderna MRNA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 22.1%-33.2pp | 55.3%+7.1pp | 48.3%-4.2pp | 52.5%-1.6pp | 54.1%-0.7pp | |
| Operating margin | -153.3%+4.8pp | -158.1%-3.0pp | -155.2%-48.8pp | -106.3%+11.0pp | -117.4%+4.5pp | |
| Net margin | -143.6%+1.6pp | -145.2%-5.6pp | -139.6%-45.3pp | -94.3%+11.4pp | -105.7%+4.4pp | |
| Returns | ||||||
| Return on equity | -36.6%-7.7pp | -28.9%+0.4pp | -29.3%-1.8pp | -27.5%+1.8pp | -29.3%-0.6pp | |
| Return on invested capital | -42.5%-6.6pp | -35.9%-2.3pp | -33.6%+0.2pp | -33.8%+1.4pp | -35.2%+0.8pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.1×0.0× | 0.2×-0.1× | 0.2×0.0× | 0.2×0.0× | |
| Liquidity | ||||||
| Current ratio | 2.4×-0.9× | 3.3×-0.6× | 3.9×0.0× | 3.9×-0.3× | 4.2×+0.5× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $18.75-15.7% | $22.24-7.1% | $23.92-1.2% | $24.22-7.1% | $26.08-8.1% | |
| Valuation | ||||||
| Market capitalization | $20.15B+74.8% | $11.52B+14.7% | $10.05B-3.0% | $10.36B-5.4% | $10.96B-31.5% | |
| Price / sales | 9.1×+3.1× | 5.9×+1.4× | 4.5×+1.1× | 3.4×-0.1× | 3.5×-1.5× | |
| Price / book | 2.7×+1.4× | 1.3×+0.3× | 1.1×0.0× | 1.1×0.0× | 1.1×-0.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Moderna's profit margins?
- Moderna (MRNA) runs a 22.1% gross margin and a -153.3% operating margin, with a -143.6% net margin.
- Where do Moderna's ratios come from?
- Every ratio is computed from Moderna's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
